Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and safety of maraviroc in neonates.
Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P; for the IMPAACT 2007 Study Team. Rosebush JC, et al. Among authors: samson p. AIDS. 2021 Mar 1;35(3):419-427. doi: 10.1097/QAD.0000000000002762. AIDS. 2021. PMID: 33252481 Free PMC article.
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.
Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, Krogstad P; IMPAACT P1101 Team. Meyers T, et al. Among authors: samson p. AIDS. 2019 Nov 15;33(14):2197-2203. doi: 10.1097/QAD.0000000000002369. AIDS. 2019. PMID: 31689263 Free PMC article. Clinical Trial.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T; International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team. Krogstad P, et al. Among authors: samson p. J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039. J Pediatric Infect Dis Soc. 2021. PMID: 32448902 Free PMC article. Clinical Trial.
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Nikanjam M, Tran L, Chadwick EG, Bwakura-Dangarembizi M, Bolton Moore C, Samson P, Spector SA, Chakhtoura N, Jean-Philippe P, Frenkel L, Zimmer B, Benns A, Libous J, Capparelli EV. Nikanjam M, et al. Among authors: samson p. AIDS. 2022 Mar 15;36(4):525-532. doi: 10.1097/QAD.0000000000003141. AIDS. 2022. PMID: 34873089 Free PMC article.
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, Heckman B, Purdue L, Spector SA, Benns A, Borkowsky W, Loftis A, Hawkins E, Wallis C, Chadwick EG; IMPAACT P1070 team. Bolton Moore C, et al. Among authors: samson p. AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463. AIDS. 2017. PMID: 28323755 Free PMC article.
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
Bwakura Dangarembizi M, Samson P, Capparelli EV, Moore CB, Jean-Philippe P, Spector SA, Chakhtoura N, Benns A, Zimmer B, Purdue L, Jackson C, Wallis C, Libous JL, Chadwick EG; IMPAACT P1070 Study Team. Bwakura Dangarembizi M, et al. Among authors: samson p. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):473-480. doi: 10.1097/QAI.0000000000002061. J Acquir Immune Defic Syndr. 2019. PMID: 31241542 Free PMC article. Clinical Trial.
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study.
Bekker A, Capparelli EV, Violari A, Cotton MF, Cababasay M, Wang J, Mathiba R, Wiesner L, Wiznia A, Samson P, Browning R, Moye J, Nakwa FL, Decloedt E, Rabie H, Mirochnick M, Cressey TR; IMPAACT P1106 team. Bekker A, et al. Among authors: samson p. Lancet HIV. 2022 Jan;9(1):e24-e31. doi: 10.1016/S2352-3018(21)00266-6. Epub 2021 Dec 6. Lancet HIV. 2022. PMID: 34883066 Free PMC article.
Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
Higa N, Pelz A, Birch D, Beck IA, Sils T, Samson P, Bwakura-Dangarembizi M, Bolton-Moore C, Capparelli E, Chadwick E, Frenkel LM. Higa N, et al. Among authors: samson p. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):261-264. doi: 10.1093/jpids/piz038. J Pediatric Infect Dis Soc. 2020. PMID: 31194860 Free PMC article.
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team. Rutstein RM, et al. Among authors: samson p. Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538. Pediatr Infect Dis J. 2015. PMID: 25232777 Free PMC article. Clinical Trial.
343 results